Current Edition

copycat

Novo Nordisk and Novartis put Victoza patent suit to bed, teeing up Sandoz copycat by 2024

After Teva Pharmaceutical snagged the OK to launch its Victoza generic in 2023, another copycat has secured a launch timeline for its generic to Novo …

Continue Reading →
divestment

Novartis CEO Narashimhan confirms interest in purchase of generics unit Sandoz

Amid Novartis’ strategic review of generics unit Sandoz, last month came word that Swedish investment group EQT and the Struengmann brothers of Germany were considering …

Continue Reading →
divestment

Novartis may have a buyer for $21B generics unit Sandoz

Amid the industrywide push by Big Pharmas to spin off their generics and consumer businesses, Novartis may be on the verge of separating itself from …

Continue Reading →
Amgen

Amgen scores Otezla patent win, protecting its blockbuster from Sandoz and Zydus generics until 2028

When Amgen bought marketing rights to psoriasis pill Otezla for $13.4 billion two years ago, the company was likely counting on not having to compete …

Continue Reading →